جستجوی مقالات مرتبط با کلیدواژه "interleukin 23 receptor" در نشریات گروه "پزشکی"

Inflammatory bowel diseases (IBDs), which include ulcerative colitis (UC) and Crohn’s disease (CD), are inflammatory disorders that affect the gastrointestinal tract. A combination of inflammatory cytokines has an important role in IBD development. Genome-wide association studies have shown that polymorphisms in the interleukin-23R gene (IL-23R) increase susceptibility to IBD. The aim of this study was to investigate the IL-23R 3' UTR SNP to determine a potential association between genotype distribution and IBD.
The case group included 102 IBD patients and the control group included 107 healthy individuals. IL-23R polymorphisms rs10889677 were genotyped using PCR-RFLP analysis. RFLP results were confirmed by direct sequencing.
The allele and genotype frequencies in patients and controls were evaluated and compared, and no significant association between this functional rs10889677 polymorphism and risk of IBD was observed (P=0.587; adjusted OR: 0.89; 95% CI: 0.597-1.339). We also found no significant association between CD (14.71%) and UC (85.29%) patients in allele or genotype levels (P>0.05).
Our results suggest that the rs10889677 A>C polymorphism is not a potential prognostic marker in Iranian patients with IBD.

Interleukin (IL)-23 has an important role in tumor immune regulation. The aim of the present study is to investigate the possible association of interleukin-23 receptor (IL23R) gene variants rs1884444, rs10889677and rs11209026 with development of acute lymphoblastic leukemia (ALL).
The IL23R variants were studied in 164 ALL patients and compared to 175 healthy controls by polymerase chain reactionrestriction fragment length polymorphism. The relationship between these variants and clinical and laboratory features of the patients and response to therapy were evaluated.
No significant differencesin genotype and allelefrequenciesexisted between patients and controls. The rs1884444TG genotype was significantly lower in patients who relapsed (24.2%) compared to those without relapse (55.9%, p=0.006).Fewer patients who relapsed had evidence of the G allele (P=0.034). The TG genotype was associated with a longer complete remission at 1804±116 days compared to other genotypes (100×103 μL (68.4% and 52.4%, respectively).
Our findings showed a lack of association of the studied polymorphisms with the risk of ALL. The influence of the rs1884444 polymorphism on relapse rate and association of rs10889677 AA genotype with favorable prognostic factors suggest the influence of the studied polymorphisms on ALL response to therapy and prognosis.